Compare PEB & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEB | AGIO |
|---|---|---|
| Founded | 2009 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2009 | 2013 |
| Metric | PEB | AGIO |
|---|---|---|
| Price | $18.33 | $34.37 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 8 |
| Target Price | $13.30 | ★ $38.88 |
| AVG Volume (30 Days) | ★ 1.9M | 1.1M |
| Earning Date | 04-28-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,475,544,000.00 | $43,011,000.00 |
| Revenue This Year | N/A | $76.75 |
| Revenue Next Year | $2.25 | $170.73 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.53 | N/A |
| 52 Week Low | $9.99 | $22.24 |
| 52 Week High | $19.93 | $46.00 |
| Indicator | PEB | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 48.72 | 51.03 |
| Support Level | $18.35 | $26.71 |
| Resistance Level | $19.73 | $36.04 |
| Average True Range (ATR) | 0.48 | 1.25 |
| MACD | -0.00 | 0.19 |
| Stochastic Oscillator | 69.78 | 59.25 |
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,052 rooms across 44 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.